Cost-saving production of gene pharmaceuticals with innovative multi-purpose biotechnological facilities based on impeller-free gas vortex bioreactor BIOK.

Piven Vladimir A., . and Ramazanov Yuri A., . and Kosyuk Ivan P., . and Mrtvetsov Nikolay P., . and Kislikh Vasiliy I., . and Repkov Andrey P., . (2003) Cost-saving production of gene pharmaceuticals with innovative multi-purpose biotechnological facilities based on impeller-free gas vortex bioreactor BIOK. [Proceedings Paper]

To match the needs of the growing industry of pharmacogenetical products for gene therapy as well as for plant microbial and animal genetics an innovative cost-effective multi-purpose biotechnological production line was developed. The pilot installation is currently operated at IMBB SB RAMS and was scaled up at the Bioproducts Plant Berdsk City Siberia. Its excellent technical and economical features based on an impeller-free gas vortex type bioreactor BIOK were demonstrated in producing recombinant human angiogenin via E. coli which is currently undergoing clinical trials for the treatment of diabetic ulcers in the University of Malaya Medical Centre. A number of other products are now being produced e.g. in mosquito control Lipidocyde tick-born encephalitis vaccine and oil drilling polysaccharides. The BIOK-process holds Russian patent PCT/RU98/00296 of 22.09.98 EU-patent pending No.98963676.6-2404 US-patent pending No. 09/787 525 Japan-patent pending No.2000-574215.

Full text available from: Official URL: https://docs.google.com/file/d/0B7urwQoldOjecUlTOU...

Abstract

To match the needs of the growing industry of pharmacogenetical products for gene therapy as well as for plant microbial and animal genetics an innovative cost-effective multi-purpose biotechnological production line was developed. The pilot installation is currently operated at IMBB SB RAMS and was scaled up at the Bioproducts Plant Berdsk City Siberia. Its excellent technical and economical features based on an impeller-free gas vortex type bioreactor BIOK were demonstrated in producing recombinant human angiogenin via E. coli which is currently undergoing clinical trials for the treatment of diabetic ulcers in the University of Malaya Medical Centre. A number of other products are now being produced e.g. in mosquito control Lipidocyde tick-born encephalitis vaccine and oil drilling polysaccharides. The BIOK-process holds Russian patent PCT/RU98/00296 of 22.09.98 EU-patent pending No.98963676.6-2404 US-patent pending No. 09/787 525 Japan-patent pending No.2000-574215.

[error in script]

Item Type:	Proceedings Paper
AGROVOC Term:	Biotechnology
AGROVOC Term:	Gene banks
AGROVOC Term:	Bioreactors
AGROVOC Term:	Experimental animals
AGROVOC Term:	Agitating
AGROVOC Term:	Aeration
AGROVOC Term:	Cell culture
AGROVOC Term:	Innovation adoption
Geographical Term:	MALAYSIA
Depositing User:	Ms. Suzila Mohamad Kasim
Last Modified:	24 Apr 2025 05:16
URI:	http://webagris.upm.edu.my/id/eprint/13661

Actions (login required)

View Item